Mrs. Santosh Lal, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 701 W North Avenue, Melrose Park, IL 60160 Phone: 847-991-7533 Fax: 847-991-7533 |
Amy Katherine Walsh, PTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 701 W North Ave, Melrose Park, IL 60160 Phone: 708-681-3200 |
Eva Fiks, M.D. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1225 W Lake St, Melrose Park, IL 60160 Phone: 708-681-3000 |
Dr. Christopher Papa, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1225 W Lake St, Melrose Park, IL 60160 Phone: 708-938-7020 Fax: 708-938-7079 |
News Archive
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
To better manage empyema in the face of rising demand for treatment, the American Association for Thoracic Surgery Guidelines Committee called for the formation of the Empyema Management Guidelines Working Group.
Shrink Nanotechnologies, Inc. ("Shrink") (OTCBB: INKN), an innovative nanotechnology company that develops products, licenses its patent-pending technologies and acquires related assets in three core vertical markets: (i) solar energy production, (ii) medical diagnostics and sensors and (iii) biotechnology research and development tools, today announced that Dr. Michelle Khine, Ph.D., the scientific founder of Shrink's nanofabrication platform, was named by MIT Technology Review as one of the top 35 global innovators under the age of 35.
In the first step toward animal-to-human transplants of insulin-producing cells for people with type 1 diabetes, Northwestern Medicine- scientists have successfully transplanted islets, the cells that produce insulin, from one species to another. And the islets survived without immunosuppressive drugs.
› Verified 3 days ago